… of amorphous itraconazole exhibiting enhanced dissolution properties were studied. Preparation
of this ternary amorphous solid dispersion … a 100 mg dose of amorphous itraconazole. …

… Obi (17) to prepare fast-release solid dispersion dosage forms. The physical mixture of a drug
and … inability to differentiate amorphous precipitation from molecular dispersion if the lattice …

Amorphous solid dispersions (ASDs) are commonly used to enhance the oral absorption of
drugs with solubility or dissolution rate limitations. Although the ASD formulation is typically …

… Despite a fairly long half-life, DLM requires twice daily dosing and must be taken … amorphous
stability and enhance the release of delamanid by developing amorphous solid dispersions …

… for drug controlled release from amorphous solid dispersions at moderate to high drug …
release rates, result in large or even multiple dosage units, which is undesirable from a patient …

… drug release from ASD is that once the water-soluble carrier starts dissolving from near
the surface, the liberated water-insoluble drug coats the surface of particles or dosage units, …

… , reducing the performance benefit of the dosage form. To inhibit drug … amorphous solid
dispersion. Due to its hygroscopic nature, the addition of the polymer to form a solid dispersion …

… amorphous solid dispersion owing to their diverse physicochemical properties. More than 20
amorphous solid dispersion-… in generation of amorphous solid dispersions. These polymers …

… solid dispersions is the most established technique for the stabilisation of amorphous forms,
… dosing to rats) compared with amorphous and crystalline furosemide acid. Importantly, the …

… as intermolecular bonds in the crystalline and pure amorphous drug system. The Gordon-…
in an amorphous dispersion, may underestimate the likely physical stability of solid dispersions …